CADL peer analysis
Candel Therapeutics (CADL) against its competitors: price, today's move, 1-year return and market value side by side.
CADL and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| GNLX Genelux | $2.07 | 5.61% | -61.81% | $93.66M |
| IMMX Immix Biopharma | $8.51 | -0.70% | 170.16% | $705.50M |
| INAB IN8bio | $0.93 | 11.63% | -44.19% | $10.01M |
| IOVA Iovance | $8.19 | 0.24% | 256.09% | $3.79B |
| IPSC Century Therapeutics | $1.75 | -3.59% | 226.29% | $315.98M |
| MGNX MacroGenics | $2.37 | 1.28% | 72.99% | $150.97M |
| NBP NovaBridge Biosciences | $0.91 | -0.08% | -77.28% | – |
| ORIC Oric | $9.11 | -1.30% | -26.23% | $944.28M |
| PBYI Puma Biotechnology | $8.27 | -1.49% | 38.06% | $426.90M |
| SNDX Syndax Pharmaceuticals | $9.72 | 1.78% | -35.37% | $875.07M |
| CADL Candel Therapeutics | $9.49 | 8.46% | 88.29% | $726.16M |
- CADL's peers: GNLX (Genelux), IMMX (Immix Biopharma), INAB (IN8bio), IOVA (Iovance), IPSC (Century Therapeutics), MGNX (MacroGenics), NBP (NovaBridge Biosciences), ORIC (Oric).
Updated 2026-11-10 15:46 UTC